Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

7.38
0.0000
Post-market: 7.30-0.0792-1.07%19:59 EDT
Volume:14.46M
Turnover:107.51M
Market Cap:7.59B
PE:-19.32
High:7.65
Open:7.37
Low:7.13
Close:7.38
52wk High:12.43
52wk Low:1.83
Shares:1.03B
Float Shares:336.00M
Volume Ratio:0.36
T/O Rate:4.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3820
EPS(LYR):-0.3820
ROE:78.05%
ROA:-36.17%
PB:-15.16
PE(LYR):-19.32

Loading ...

US FDA: Sends Warning Letter to Immunitybio, Inc for "False or Misleading" Tv Ad and Podcast on Anktiva

THOMSON REUTERS
·
Mar 24

US FDA : Immunitybio Ads "Misleadingly" Claims Anktiva Can Cure, Prevent All Cancer-Website

THOMSON REUTERS
·
Mar 24

ImmunityBio falls -23.0%

TIPRANKS
·
Mar 24

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 23

ImmunityBio call volume above normal and directionally bullish

TIPRANKS
·
Mar 23

ImmunityBio Gains First Asian ANKTIVA Nod As Cell Therapy Story Builds

Simply Wall St.
·
Mar 22

ImmunityBio (IBRX) Is Up 12.8% After NCCN Expands ANKTIVA Bladder Cancer Guideline Inclusion - What's Changed

Simply Wall St.
·
Mar 21

BRIEF-Immunitybio Announces Approval In Macau SAR, China For Anktiva

Reuters
·
Mar 21

ImmunityBio announces approval in Macau for Anktiva

TIPRANKS
·
Mar 21

Macau SAR Regulator Approves ImmunityBio ANKTIVA for BCG-Unresponsive NMIBC CIS

Reuters
·
Mar 21

Immunitybio Announces Approval in Macau SAR, China for Anktiva® in Bcg-Unresponsive Nmibc With CIS ± Papillary Tumors

THOMSON REUTERS
·
Mar 21

Assessing ImmunityBio (IBRX) Valuation After NCCN ANKTIVA Update And NK Cell Therapy Progress

Simply Wall St.
·
Mar 19

Mixed options sentiment in ImmunityBio with shares up 3.53%

TIPRANKS
·
Mar 18

The Stubborn Billionaire Behind the L.A. Times's Revamp -- WSJ

Dow Jones
·
Mar 18

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 17

ImmunityBio announces NCCN Guidelines for Bladder Cancer to include Anktiva

TIPRANKS
·
Mar 17

ImmunityBio cites QUILT-3.032 data as NCCN adds ANKTIVA plus BCG for BCG-unresponsive papillary-only NMIBC

Reuters
·
Mar 17

Immunitybio Announces Nccn® Clinical Practice Guidelines in Oncology Have Been Updated to Include Anktiva® Plus Bcg for Patients With Bcg-Unresponsive Nmibc With Papillary-Only Disease

THOMSON REUTERS
·
Mar 17

Mixed options sentiment in ImmunityBio with shares down 2.26%

TIPRANKS
·
Mar 17

Update: ImmunityBio Shares Rise After Completion of Scalable M-ceNK Manufacturing Pathway

MT Newswires Live
·
Mar 14